Skip to main content
The Markets by Proactive
Go to Proactive UK
Proactive UK has moved. Proactive’s coverage of London’s small caps continues on proactiveinvestors.com Go there →
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Coverage of London’s small caps continues on proactiveinvestors.com
Go to Proactive UK
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK

Pharma & Biotech

Sensyne Health inks strategic research agreement with US healthcare provider

The tie-up with St Luke's University Health Network in Pennsylvania will provide it with access 2.5mln ‘de-identified' patient records

Sensyne Health PLC (LON:SENS), which uses AI technology to ethically use mass patient data to support medical research, has signed a strategic research agreement with an American healthcare provider.

The tie-up with St Luke's University Health Network in Pennsylvania will provide it with access 2.5mln ‘de-identified' patient records.

In return for providing Sensyne access to the material, St Luke’s will receive 115,541 shares along with 346,621 warrants that allow it to invest at a certain price at a later date.

The latest agreement is one in a series of similar strategic research agreements that will provide Sensyne with access thus far to 8.5mln patient records.

“Healthcare data saves lives, and our aim is to build the world's best resource for the ethical use of anonmymised and de-identified patient data for medical research. This new partnership represents an important step towards that goal,” said Lord Drayson, Sensyne’s chief executive.

Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK